Shanghai INT Medical Instruments Co., Ltd. (INT Medical) has issued a notice convening its annual general meeting (AGM) for 2:00 p.m. on 28 May 2026 at Block 2, No. 925 Jin Yuan Yi Road, Jiading District, Shanghai.

Key items to be put before shareholders are as follows:

1. 2025 Reporting Package • Directors’ Report, Supervisory Committee Report, the 2025 Annual Report and audited financial statements are up for endorsement. • A profit-distribution proposal for the year ended 31 December 2025 will be voted on; details will be released in the accompanying circular.

2. 2026 Operating Framework • The Group’s 2026 financial budget and the remuneration plan for directors for the year ending 31 December 2026 require shareholder approval. • Re-appointment of KPMG and KPMG Huazhen LLP as international and domestic auditors, respectively, with the Board authorised to fix their fees.

3. Capital Management Mandate • The Board seeks a 12-month general mandate to repurchase up to 10% of both H shares and domestic shares in issue (excluding any treasury shares). • The mandate authorises directors to set timing, price and volume, handle regulatory filings, cancel repurchased shares and amend the Articles of Association accordingly. • The mandate expires at the earlier of the next AGM, 12 months from approval, or a subsequent shareholder resolution revoking or varying the authority.

4. Corporate Governance Change • A special resolution proposes abolishing the Supervisory Committee and amending the Articles of Association to reflect the new governance structure.

Key Timetable • Share-transfer registration for AGM voting entitlement closes from 28 April 2026 to 28 May 2026 (both days inclusive); the record date is 28 May 2026. • Subject to AGM approval of the 2025 dividend, the register closes again from 5 June 2026 to 10 June 2026, with 10 June 2026 set as the dividend record date.

Shareholders may appoint proxies to vote on their behalf by lodging forms at Computershare Hong Kong Investor Services Limited (for H-shareholders) or the company’s registered office in Shanghai (for domestic shareholders) no later than 24 hours before the AGM.

The Board currently comprises two executive directors, four non-executive directors and three independent non-executive directors, chaired by Dr. Liang Dongke.